Roche's Lunsumio granted Priority Review by FDA for people with relapsed or refractory ...

Retrieved on: 2022-07-07 12:08:07

Tags for this article:

Click the tags to see associated articles and topics

Roche's Lunsumio granted Priority Review by FDA for people with relapsed or refractory .... View article details on hiswai:

Excerpt

Roche's Lunsumio (mosunetuzumab) has been given a Priority Review by the US Food and Drug Administration (FDA) following its acceptance of the ...

Article found on: www.pmlive.com